Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELDN NASDAQ:IRD NASDAQ:SNDL NASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$3.85-6.8%$3.79$1.35▼$4.60$318.79M0.951.84 million shs1.39 million shsIRDOpus Genetics$3.92-2.5%$4.31$1.04▼$5.81$331.92M0.551.12 million shs598,438 shsSNDLSNDL$1.31$1.41$1.28▼$2.89$337.19M0.922.23 million shs1.27 million shsTELOTelomir Pharmaceuticals$1.23-3.1%$1.27$1.05▼$3.10$87.34M-0.25127,338 shs29,890 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals-6.78%-2.53%+11.27%+24.19%+13.24%IRDOpus Genetics-2.49%-7.33%+0.77%-26.87%+253.15%SNDLSNDL0.00%-4.73%-9.66%-7.75%-7.75%TELOTelomir Pharmaceuticals-3.15%-3.15%-0.81%+0.82%+4.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$3.85-6.8%$3.79$1.35▼$4.60$318.79M0.951.84 million shs1.39 million shsIRDOpus Genetics$3.92-2.5%$4.31$1.04▼$5.81$331.92M0.551.12 million shs598,438 shsSNDLSNDL$1.31$1.41$1.28▼$2.89$337.19M0.922.23 million shs1.27 million shsTELOTelomir Pharmaceuticals$1.23-3.1%$1.27$1.05▼$3.10$87.34M-0.25127,338 shs29,890 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals-6.78%-2.53%+11.27%+24.19%+13.24%IRDOpus Genetics-2.49%-7.33%+0.77%-26.87%+253.15%SNDLSNDL0.00%-4.73%-9.66%-7.75%-7.75%TELOTelomir Pharmaceuticals-3.15%-3.15%-0.81%+0.82%+4.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals 2.40Hold$9.67151.08% UpsideIRDOpus Genetics 2.88Moderate Buy$10.77174.73% UpsideSNDLSNDL 2.00Hold$5.00281.68% UpsideTELOTelomir Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest TELO, IRD, SNDL, and ELDN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026IRDOpus Genetics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.007/6/2026IRDOpus Genetics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.006/24/2026ELDNEledon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/23/2026IRDOpus Genetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.006/23/2026IRDOpus Genetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageModerate Buy$10.006/18/2026IRDOpus Genetics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $13.006/17/2026IRDOpus Genetics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/17/2026IRDOpus Genetics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.006/16/2026IRDOpus Genetics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.006/15/2026IRDOpus Genetics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$11.006/11/2026SNDLSNDL Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$1.35 per shareN/AIRDOpus Genetics$14.20M22.79N/AN/A$0.22 per share17.82SNDLSNDL$677.32M0.50$0.11 per share11.63$3.06 per share0.43TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$45.62M-$0.77N/AN/AN/AN/A-116.97%-41.91%8/13/2026 (Estimated)IRDOpus Genetics-$49.59M-$1.33N/AN/AN/A-892.36%-338.88%-191.21%8/12/2026 (Estimated)SNDLSNDL-$11.29M-$0.03N/A32.75N/A-1.19%-1.02%-0.85%7/30/2026 (Estimated)TELOTelomir Pharmaceuticals-$10.41M-$0.29N/AN/AN/AN/A-201.23%-172.71%9/2/2026 (Estimated)Latest TELO, IRD, SNDL, and ELDN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2026Q2 2026SNDLSNDL-$0.01N/AN/AN/A$166.26 millionN/A5/14/2026Q1 2026TELOTelomir Pharmaceuticals-$0.07-$0.03+$0.04-$0.03N/AN/A5/13/2026Q1 2026ELDNEledon Pharmaceuticals-$0.22-$0.33-$0.11-$0.33N/AN/A5/12/2026Q1 2026IRDOpus Genetics-$0.16-$0.75-$0.59-$0.75$2.93 million$2.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A8.448.44IRDOpus GeneticsN/A7.137.13SNDLSNDL0.124.843.25TELOTelomir PharmaceuticalsN/A7.007.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%IRDOpus Genetics14.97%SNDLSNDLN/ATELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals9.60%IRDOpus Genetics11.70%SNDLSNDLN/ATELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals1077.19 million69.78 millionOptionableIRDOpus Genetics1482.57 million72.91 millionN/ASNDLSNDL2,751257.40 millionN/AOptionableTELOTelomir Pharmaceuticals168.78 millionN/AN/ATELO, IRD, SNDL, and ELDN HeadlinesRecent News About These CompaniesTELO Telomir Pharmaceuticals, Inc.July 8 at 5:26 PM | seekingalpha.comTelomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical ...June 15, 2026 | usatoday.comTelomir Showcases Preclinical Telomir-Zn Diabetes Efficacy DataJune 15, 2026 | tipranks.comTelomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes ModelJune 15, 2026 | accessnewswire.comATelomir Pharmaceuticals Appoints Fractional CFO After Leadership ChangeJune 8, 2026 | tipranks.comTelomir Pharmaceuticals Inc TELOMay 26, 2026 | morningstar.comMTelomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s DiseaseMay 20, 2026 | usatoday.comTelomir-Zn Preclinical Data Published in Wilson’s DiseaseMay 20, 2026 | tipranks.comTelomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's DiseaseMay 20, 2026 | accessnewswire.comATelomir Pharmaceuticals Receives FDA IND Clearance for Telomir-ZnApril 30, 2026 | tipranks.comTelomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast CancerApril 30, 2026 | accessnewswire.comATelomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)April 24, 2026 | usatoday.comTelomir Pharmaceuticals Inc.April 2, 2026 | barrons.comTelomir seeks FDA approval for Telomir-1 to treat breast cancerApril 2, 2026 | msn.comTelomir Pharmaceuticals Regains Nasdaq Listing Rule ComplianceMarch 31, 2026 | tipranks.comTelomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast CancerMarch 31, 2026 | accessnewswire.comATelomir Shareholders Approve Equity Plan and Bylaw ChangesMarch 27, 2026 | tipranks.comTelomir Pharmaceuticals Faces Crucial Corporate and Regulatory DeadlinesFebruary 21, 2026 | aktiencheck.deATelomir Sets Vote on Transformative TELI Merger and Governance ChangesFebruary 19, 2026 | tipranks.comTelomir reveals promising preclinical data for Telomir-ZnFebruary 17, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAST SpaceMobile Announces Launch Date for Its Next 3 BlueBird SatellitesBy Jessica Mitacek | June 16, 2026AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?By Jessica Mitacek | June 26, 2026AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in FocusBy Jessica Mitacek | July 3, 2026Rocket Lab Defies Gravity With $8B BuyoutBy Jeffrey Neal Johnson | June 30, 2026Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive WeaponBy Jeffrey Neal Johnson | July 2, 2026TELO, IRD, SNDL, and ELDN Company DescriptionsEledon Pharmaceuticals NASDAQ:ELDN$3.85 -0.28 (-6.78%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$3.92 +0.07 (+1.92%) As of 07/10/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Opus Genetics NASDAQ:IRD$3.92 -0.10 (-2.49%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$4.00 +0.08 (+1.91%) As of 07/10/2026 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.SNDL NASDAQ:SNDL$1.31 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$1.31 0.00 (0.00%) As of 07/10/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.Telomir Pharmaceuticals NASDAQ:TELO$1.23 -0.04 (-3.15%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$1.25 +0.02 (+1.71%) As of 07/10/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/06 - 07/10 Why WD-40 Is Proving Great Businesses Never Go Out of Style Rocket Lab’s Stock Drop Comes With a Bullish Twist Power Struggle: Wolfspeed Sues Navitas Over AI Chips Pushing the Edge: Super Micro Computer Reboots the AI Landscape Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
